



2009 Meeting At-A-Glance Day 1 Monday, April 20



7:30 AM - 5:30 PM

Registration

8:00 AM - 9:00 AM
Westside Ballroom South

Coffee and Continental Breakfast (in exhibit hall)

8:00 AM - 6:30 PM
Westside Ballroom South

Exhibit Hall Open

9:00 AM - 10:15 AM

Panel Session 1

Imperial/Juilliard

1A: Funding Early-Stage Companies in Challenging Economic Climate

Presented by: Alzheimer's Drug Discovery Foundation

Early-stage biotechnology companies great challenge is securing funding from public and private sources. Disease specific foundations engaged in venture philanthropy are increasingly supporting early-stage companies while venture capitalists tend to fund later-stage biotechnology companies. The proposed panel will discuss how venture capitalists and venture philanthropic organizations can partner to leverage their financial resources as well as their operating and financial expertise to support early-stage biotechnologies companies.

Panel Chairman: Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation

Panel Speakers: Allan Green, MD, PhD, JD, Partner, Allan M. Green Esq., LLC

Peter Lomedico, PhD, Director of Industry Partnerships, Juvenile Diabetes Research Foundation

Stephen Sands, Managing Director and Global Co-Head of Healthcare Investment Banking, Lazard Frères & Co.

Barbara Dalton, PhD, Vice President for Venture Capital, Pfizer Inc.

Carnegie/Lyceum

1B: 2009 Annual Biotech Patent Law Update

Presented by: Kenyon & Kenyon LLP

This panel will review and discuss current challenges and trends in patent law affecting the biotech and pharmaceutical industry. Ranging from litigation to licensing, from patent prosecution to proposed patent reform, from the district courts to the Supreme Court, and including important issues in major regions outside the U.S., this panel will serve as a convenient way for business, technical, and legal department personnel to keep up to speed on the ever evolving dynamics of biotech patent law.

Panel Chairman: Deborah Somerville, Esq., Partner, Kenyon & Kenyon LLP

Panel Speakers: Peter A. Cicala, Esq., Vice President of Intellectual Property, Shire Pharmaceuticals

Gloria M. Fuentes, Legal Director, Patents, Schering-Plough Corporation

Thomas C. Gallagher, Esq., Consultant, Neostem Inc.

Charles A. Weiss, Esq., Partner, Kenyon & Kenyon LLP

Broadhurst

1C: Nanotechnology and Life Science: Business and Science Perspective

Presented by: The Livingston Group

Nanotechnology is impacting a wide range of sectors from energy, defense, materials, to life sciences. There are a number of key challenges in drug discovery and diagnostics that nanotechnology has shown early impact and a significant promise. Examples include successful development and marketing of novel and nano-formulation of number of drugs to treat cancer, as well as highly precise diagnostics. The level of interest and engagement is certainly spreading beyond small and emerging companies to medium and large players in life sciences. The conventional routes for financing include venture capital funds either specializing in Life Science and/or nanotechnology. With increasing expectation of exits and tightening of credit market there is a great deal of interest in identifying sources to continue support of promising R&D in this area. In this panel discussion, we will have key science and business leaders discussing their current state of affair, key challenges for moving forward, and future trends.

Panel Chairman: Mostafa Analoui, Head of Life Sciences and Healthcare, The Livingston Group

Panel Speakers: Wendy Sanhai, PhD, Senior Scientific Advisor, Office of the Commissioner, FDA

Doug Jamison, CEO, Harris and Harris Group, Inc.

Jeff Davidson, CEO, Keystone Nano, Inc.

Travis M. Earles MS/MBA, Co-Chair, Subcommittee on Nanoscale Science, Engineering, & Technology, National Science and Technology Council



2009 Meeting At-A-Glance Day 1 Monday, April 20



9:00 AM - 10:15 AM

Alvin

Panel Session 1 (continued)

1D: The Continuing Challenges of Managing Your Immigration Strategies Effectively

Presented by: Opus Scientific, LLC

Recruiting and retaining talent often involves consideration and understanding of the immigration process. This program will provide an update on current business immigration and examine strategies for preparing for and adapting to evolving legal issues including H-1B Visa Cap and Green Card processing. The program will also include an update on I-9 compliance concerns such as SSA's "No Match" letter program and conclude with a legislative and regulatory update.

Panel Chairman: Bill Manning, Head of Immigration Dept., Jackson Lewis LLP

Panel Speakers: Ethan E. Kaufman, Esq., Partner, Fragomen, Del Ray, Bernsen & Loewy, LLP

Ayesha C. Blackwell, Associate Counsel, Bristol-Myers Squibb

9:00 AM - 10:15 AM
Belasco

Bioscience Industry Showcase

9:00 AM - 12:00 PM
Westside Ballroom
North-Foyer

Innovation Alley Session 1

10:15 AM - 10:30 AM

Coffee Break (in exhibit hall)

10:30 AM - 11:45 AM

Imperial/Juilliard

Panel Session 2

2A: Out of Academia and Into Industry: Commercializing Academic Research

Presented by: Cooley Godward Kronish LLP

Academic research institutions play a vital role in the ecosystem of the New York market's biotech community and, in fact, are a significant factor in where our community ranks as a viable biotech marketplace on the national scene. These institutions are the breeding ground for the innovation and product development that fuels the pipeline of the biotechnology industry. Yet the very same developers of the latest solutions in life sciences and biotechnology face a whole new set of challenges when their new inventions and products are ready for prime time. How can academic research institutions and their entrepreneurs prepare to most effectively go to market? What has been the key for successful conversion from idea to licensed product? How have academic research institutions aligned themselves effectively in the business and deal flow community to ensure that movement from academia to industry is seamless? This panel, led by Thomas Meyers, partner of Cooley Godward Kronish's nationally renowned life sciences practice, will look at the successful conversion of academic technology into commercial technology and feature panelists from academic research institutions in the New York market such as NYU and Columbia and best of breed from other markets – MIT and Johns Hopkins – to discuss the paths and pitfalls from the quad to Wall Street. Cooley's national life sciences practice ranks #1 nationally* and represents over 600 private life sciences companies.

Panel Chairman: Thomas Meyers, Partner, Cooley Godward Kronish LLP

Panel Speakers: Abram Goldfinger, New York University

Alan Paau, Executive Director of Office of Commercialization, Cornell University

Carnegie/Lyceum

2B: The Biotechnology Catcher's Mit

Presented by: Phase 3 Properties, Inc.

NYBA has assembled industry leaders to analyze NY's existing tech-facility incubator infrastructure. We will be taking a close look at how NY compares to the other US tech markets on cost, incentives and accessibility. Further, we will hear from some of the leading NY university commercialization executives on tech-transfer success and future incubator needs.

Panel Chairman: Warner A. Bonner, III, Principal, Phase 3 Properties

Panel Speakers: Eva Cramer, PhD., VP for Biology Affairs at SUNY & President of BIOBAT, SUNY & BIOBAT

David Hochman, Executive Director, Business Incubator Association of NY State Inc.

Bill Peters, Senior Vice President, Jones Lang LaSalle Life Sciences Group

Orin Herskowitz, Executive Director, Science and Technology, Columbia University

Brian Kelly, Director, Cornell Center for Technology Enterprise and Commercialization (CCTEC)

Richard Charles, First Vice President, CB Richard Ellis, Inc.



2009 Meeting At-A-Glance Day 1 Monday, April 20



10:30 AM - 11:45 AM

Broadhurst

Panel Session 2 (continued)

2C: Synthetic Biology: International Regulatory and Legal Issues Around a Rising Industry

Presented by: **Foley & Lardner**

This session introduces synthetic biology as a fast growing field of science and engineering, one that presents unique regulatory and commercial challenges. The session will discuss current legal concerns relevant to synthetic biology research and the commercialization of synthetic biology products. The state of federal regulations relating to synthetic biology and its dual-use potential will be discussed; the existing intellectual property and patent landscapes will be presented, as well as international regulatory and legal frameworks that may affect the prospects for development of this field. Both topics will be framed within the context of how not-for-profit and for-profit research and industry are affected.

Panel Chairman: Mark Waxman, Partner, Foley & Lardner LLP

Panel Speakers: Steve Bent, Partner, Foley & Lardner LLP

Kevin O'Connell, In-Q-Tel, Inc.

Jason Kelly, Ph.D., DNA Hacker, Ginkgo BioWorks

Cord F. Staehler, CEO, febit holding gmbh, President febit biomed gmbh & febit inc.

Alvin

2D: Tools and Techniques to Turn Your Scientists into Leaders

Presented by: **Opus Scientific LLC**

This panel will be a part 2 of a well received break-out last year "Turning Your Scientist into a Leader". The panel meshed well and delivered a perspective from talent development human resources, line management, corporate trainers and coaches. Taking the development to the next level, this panel will address mentoring and executive coaching to develop organizational leaders.

Panel Chairman: Kathy Bernhard, President, KFB Leadership Solutions

Panel Speakers: Gaylene Xanthopoulos, President, The Leadership Edge, Inc.

Casey DeBruyn, MSM Training Supervisor, Invitrogen Corporation

Amy Sheehan, HR, OSI Pharmaceuticals, Inc.

10:30 AM - 11:45 AM

Belasco

Bioscience Industry Showcase

12:00 PM - 1:30 PM

Westside Ballroom
North

Lunch and Keynote: Billy Tauzin, CEO, PhRMA



Billy Tauzin

1:30 PM - 4:30 PM

Innovation Alley Session 2

1:30 PM - 2:45 PM

Panel Session 3

Imperial/Juilliard

3A: Crisis? What Crisis: Approaching the Brave New World of Biotech Financing Survival

Presented by: **Acorda Therapeutics, Inc.**

How to design and implement effective financing strategies and other creative alternatives for extending biotech survival in the current economic environment. Financial, investment, investor relations and biotech experts will explore the impact on and perspective of different types of investors; corporate development, collaboration and product-driven funding as financing strategies; the impact of the current drug regulatory environment; and, successful bear market IR/PR tools and strategies.

Panel Chairman: Jane Wasman, Executive Vice President/General Counsel, Acorda Therapeutics, Inc.

Panel Speakers: Robert H. Glassman, M.D., Managing Director, Healthcare Investment Banking, Merrill Lynch & Co.

Lilian Stern, Principal, Stern Investor Relations

Andrew J. Weisenfeld, Senior Managing Director, MTS Health Partners

Jonathan Silverstein, General Partner, OrbiMed Advisors LLC



2009 Meeting At-A-Glance Day 1 Monday, April 20



1:30 PM - 2:45 PM

Carnegie/Lyceum

Panel Session 3 (continued)

3B: Academia & Corporate Partnerships: The Grooming of Next Generation Scientists

Presented by: OSI Pharmaceuticals Foundation, Inc

The need to encourage the next generation to pursue science as a career is greater than ever! Find out how partnerships are formed between business and academia (coordinated and directed by experienced third party advisors) to encourage the exploration of biotechnology as a potential career field. Learn how a Fellows Mentoring Program works and the benefits for educational institutions and for companies. Hear personal experiences from a local graduate student (mentee) and pharmaceutical employee (mentor) involved in a win-win partnership.

Panel Chairman: Ann McDermott-Kave, Director, OSI Pharmaceuticals Foundation, Inc.

Panel Speakers: Paul Hanle, President, Biotechnology Institute

Lan Hu, Ph.D., Senior Director, Business Development, OSI Pharmaceuticals, Inc.

Alyson Kass-Eisler, Ph.D., Curriculum Director and PostDoc Officer, Watson School of Biological Sciences, Cold Spring Harbor Laboratory

Dr. Clinton T. Rubin, Director, Center for Biotechnology

Onika Murray, Graduate Student, Stony Brook University

Broadhurst

3C: Vaccines: Progress and New Challenges

Presented by: NaniRx Therapeutics

This panel will address how state-of-the-art technology is impacting 4 key spaces: 1) cancer vaccines; 2) influenza vaccines; 3) adjuvants; and 4) HIV vaccines as well as new challenges to the industry posed by the clinical development of new vaccine technologies.

Panel Chairman: David Cohen, CEO, NaniRx Therapeutics

Panel Co-chairman: Dana Abrassart, Program Director, NaniRx Therapeutics

Panel Speakers: Rahul Singhvi, CEO, Novavax, Inc,

Francois Simon, Professor, CHU Saint-Louis-Paris

David O'Neill, Director, NYUCI Vaccine and Cell Therapy Core Facility, New York University School of Medicine

Dr. Robert L Coffman, Vice President and Chief Scientific Officer, Dynavax Technologies

Alvin

3D: Partnering Strategies in Europe

Presented by: Catalonia Investment Agency/The European-American Business Organization/Flanders Investment and Trade

Europe represents the second largest market for biotechnology products, and is growing at least as rapidly as the US market. For any company, entrepreneur or researcher seeking partners, customers, or other relationships, Europe is a vital piece of any global market strategy. In this session, learn about the opportunities Europe has for your business development.

Panel Chairman: John Zindar, Partner, The European-American Business Organization, Inc.

Region-Catalonia

Clara Barreneche, Executive Director, Catalonia Trade and Investment-New York (ACC10 CIDEM|COPCA), Government of Catalonia

Dr. Montserrat Vendrell, CEO, Catalonia BioRegion (BIOCAT)

Region-Flanders

Jan Wauters, Vice President, Flanders Investment & Trade

1:30 PM - 2:45 PM

Belasco

Bioscience Industry Showcase

2:45 PM - 3:00 PM

Coffee Break (in exhibit hall)



2009 Meeting At-A-Glance Day 1 Monday, April 20



3:00 PM - 4:15 PM

Imperial/Juilliard

Panel Session 4

4A: Buying, Selling and Dealing with Biotech Assets in the Distressed Financial Environment

Presented by: Mintz, Levin, Cohn, Ferris, Glovsky, & Popeo, P.C.

The current financial crisis is having a significant adverse effect on the biotechnology industry. Cash is dwindling for many life-science firms, with around one hundred of the publicly traded biotechnology companies running on less than six months' worth of cash. And in the bleak economic atmosphere, raising new capital through investors, public stock offerings and bank loans is increasingly challenging. Biotechnology companies without substantial balance sheets must now make difficult decisions. This panel will focus on the choices that struggling life-science firms can make, including the sales of assets, the licensing of drugs in its pipeline and the sales of future royalties. The panel will also discuss the concerns from a buyer's standpoint, such as the potential for life-science firms to file for bankruptcy after a sale of an asset.

Panel Chairman: Joel I. Papernik, Esq., Member, Business and Finance Section,
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Panel Speakers: David Ghesquiere, Vice President, Corporate & Business Development, OSI Pharmaceuticals, Inc.
Stephen Sands, Managing Director, Lazard Frères & Co.

Noah J. Kroloff, Partner, NGN Capital

Otello Stampacchia, Investment Advisor, Omega Funds Management, Ltd.

Carnegie/Lyceum

4B: Biotech R&D Funding – The SBIR Program

Presented by: New York City Economic Development Corporation

The panel will highlight R&D funding opportunities for bioscience companies (and academic researchers with a commercial interest) from the \$2 Billion Federal SBIR/STTR program. The panel will feature content experts from the National Institutes of Health, SBIR award winners and SBIR reviewers. Confirmed speakers include Ms. Jo Anne Goodnight, NIH SBIR/STTR Program Coordinator. This one-day conference is perfect for small biotechnology businesses to learn how to take advantage of Federal funding for small biotech companies. Learn how to get your share of \$2 Billion in undiluted funding to advance bioscience research.

Panel Chairman: Lenzie Harcum, Vice President, Biosciences, New York City Economic Development Corporation

Panel Speakers: Jo Anne Goodnight, NIH SBIR/STTR Program Coordinator,

National Institutes of Health Office of Extramural Research

Dr. James Moe, President and CEO, Oligomerix, Inc.

Dr. Andre Fenton, CEO, Bio-Signal Group Corp.

Jack McGowan, Project Manager, Insyte Consulting



2009 Meeting At-A-Glance Day 1 Monday, April 20



3:00 PM - 4:15 PM

Broadhurst

Panel Session 4 (continued)

4C: Evidence-Based Medicine: How Will it Shape Healthcare in the Coming Decades

Presented by: Arnold Consultancy & Technology LLC

According to the Institute of Medicine Roundtable on Evidence-Based Medicine, with "per capita expenditures more than 20 percent higher than any other country in the world and more than twice the average expenditure for European countries, the nation ranks well below at least two dozen others on key health indices such as infant survival and life expectancy." What's the problem? Lack of application of the best evidence to medical decision-making, both to individual patients and to patient populations as a whole. Will we have government regulation imposed on us, such as the U.K.'s National Institute for Health and Clinical Excellence (NICE), the NHS' cost-effectiveness watchdog? Can we monitor ourselves using well-established methods, such as outcomes registries, retrospective database analysis and cost-effectiveness analysis, to generate the evidence we need to rein in our spiraling healthcare costs, while improving patient outcomes?

Panel Chairman: Sarah Evans, VP Evidence-Based Medicine, Arnold Consultancy & Technology LLC

Panel Speakers: Dr. Renée Arnold, PharmD, President and CEO, Arnold Consultancy & Technology LLC

Dr. Teresa Zyczynski, PharmD, MBA, MPH, Sr. Director Health Economics & Outcomes Research, GE Healthcare

Stuart McConchie, Vice President, Jarvik Heart, Inc.

Jianwei Xuan, MD, PhD, Emerging Markets Business Units, Pfizer Inc.

Alvin

4D: Employee Development Program Alliances with Academia. The Hidden Benefits!

Presented by: Opus Scientific LLC

This session will address cooperation between academic and industry with regard to meeting industry training objectives. Panelists will be representative of varied educational institutions and training centers discussing the programs offered, their corporate training relations and the talent pool graduating from their programs. Audience interaction will be encouraged as corporate needs are an integral part of course development and NYSED approval.

Panel Chairman: Diana Bartelt, Director & Associate Professor, St. John's University

Panel Speakers: Arthur Zeitlin, Professor & Chairman, Kingsborough Community College

Jim Hewlitt, New York Hub Director, Biomanufacturing Center and Collaborative

Douglas Merrill, Professor and Director, Rochester Institute of Technology

Amy Sheehan, HR, OSI Pharmaceuticals, Inc.

Patricia Rockwell, Director of the BA/MA Degree in Biology, Hunter College

3:00 PM - 4:15 PM

Belasco

Bioscience Industry Showcase

4:30 PM - 6:30 PM

Westside Ballroom
South

Gala Reception (in exhibit hall)

Sponsored by Conner Strong Companies Inc.





2009 Meeting At-A-Glance Day 2 Tuesday, April 21



7:00 AM - 8:30 AM
Booth

Government Relations Advisory Group Breakfast

Sponsored by Genentech, Inc.
(Invitation Only)

7:00 AM - 8:30 AM
Edison

CEO Breakfast

(Invitation Only)

7:30 AM - 8:30 AM
Westside Ballroom
South

Coffee and Continental Breakfast (in exhibit hall)

7:30 AM - 1:00 PM

Registration

7:30 AM - 2:30 PM
Westside Ballroom
South

Exhibit Hall Open

8:30 AM - 9:45 AM

Session 5

Imperial/Juilliard

5A: Paying (and Not Paying) for Expensive Drugs

Presented by: Scisive Consulting LP

Health care in the U.S. is broken. On the one hand there is demand from patients for ever-more sophisticated (and expensive) products and technologies; on the other hand payers' funds are not limitless and capacity constraints are inevitable. In Europe, particularly in France, Germany and the U.K., new governmental organizations have been charged with ensuring that cost-efficacy is measured together with quality in determining national protocols for best medical practice. Scisive Consulting will lead a panel discussion on the successes (and failures) of these organizations in containing costs while optimizing care, and consider the implications for health care in the U.S.

Panel Chairman: Catherine Staughton, Founder, Scisive Consulting LP

Panel Speakers: Gabe Leung, President, OSI Oncology, OSI Pharmaceuticals, Inc.

Jeremy Levin, Senior Vice President, Strategic Transactions, Bristol-Myers Squibb

Dr. Farid Boulad, Medical Director, Pediatric Day Hospital, Memorial Sloan Kettering Cancer Center

Dr. Ron Aran, Chief Medical Officer, Emblem health

Carnegie/Lyceum

5B: Issues in Biotechnology Patenting: Are Prosecutors and Litigators on the Same Page and Can They Get There?

Presented by: Ropes & Gray LLP

The interplay of practicalities and necessities of patent prosecution and patent litigation provides opportunities for cooperation and for tension. Our panel of prosecutors and litigators will provide a lively back and forth from their different perspectives on four topics that are timely and relevant to biotechnology: Creating a Patent Office record/Litigating one; Disclosure obligations in view of Dayco, McKesson etc and their effect on patent prosecution and litigation; Presenting biotechnology in an understandable way in a patent application and to a jury; and The effects of Bilski, Labcorp, Prometheus etc. on obtaining and litigating biological marker and diagnostic method claims.

Panel Chairman: Jane T. Gunnison, Partner, Ropes & Gray LLP

Panel Speakers: Christopher J. Harnett, Partner, Ropes & Gray LLP

Denise Loring, Partner, Ropes & Gray LLP

Jane A. Massaro, Esq., Senior Corporate Counsel, Pfizer Inc.



2009 Meeting At-A-Glance Day 2 Tuesday, April 21



8:30 AM - 9:45 AM

Broadhurst

Panel Session 5 (continued)

5C: Enterprise Risk Management for Life Science Companies

Presented by: **Conner Strong Companies, Inc.**

Increasing and intense regulatory scrutiny continues to "raise the bar" for today's pharmaceutical and biotech organizations. Market pressures and ever changing regulations are amplifying business and operational risk. This panel will discuss governance, risk and compliance (GRC) processes and the reasons why many companies are now integrating proactive risk management techniques into their Corporate Compliance Programs. Hear visionary perspectives to the challenges that lie ahead and insight from Chief Compliance Officers as to the evolving and important role that Risk Management principles are assuming as the industry rides the next tide of compliance challenges.

- The current compliance landscape
- Reasons why a proactive Risk Management program complements the goal of a sustainable Corporate Compliance program
- Platforms and processes to efficiently detect and deter risks
- The role that ERM can play in driving business performance improvements and value

Panel Chairman: John Pennett, Amper Politziner

Panel Speakers: Ken Pina, Partner, Core Risk Ltd.

Teresa Garrison, Vice President, Global Life Science Practice, Conner Strong Companies, Inc.

Deborah Penza, Vice President of Corporate Compliance, Elan

Alvin

5D: How to do Business with the University

Presented by: **Center for Economic Growth and Bioconnex**

This panel will attempt to open a window on the university allowing biotech companies, technologists and others to better understand the services, facilities, collaboration and purchasing possibilities available in the university. We will cover university policies, research centers and technology transfer.

Panel Chairman: Eugene K. Schuler, Chair, Bioconnex

Panel Speakers: Joseph Scaduto, Assistant Director of Business Development, Center for Biotechnology

Kathleen A. Denis, PhD, Associate VP of Technology Transfer, The Rockefeller University

Belasco

5E: Pharma & Biotech on the Web

Presented by: **Axxiem Web Solutions**

The web is an essential tool for Pharma & Biotech companies today. From simple front-end marketing, product or patient community sites, to intranets and extranets, this panel will discuss the latest trends on the Web, as well as the future for this important component of Pharma/Biotech companies' operations and marketing strategy.

Panel Chairman: Susan Lewenz, President/CEO, Axxiem Web Solutions

Panel Speakers: Rebecca Hyde, Partner, Strategyx

Terri Roberson, Manager of Operations, Eli Lilly

Karen Massand, Managing Director, Strategic Advisory Group, Skila

Kelly Angelini, President, Simpson Healthcare

9:00 AM - 12:00 PM

Westside Ballroom
North-Foyer

Innovation Alley Session 3

9:45 AM - 10:15 AM

Coffee Break (in exhibit hall)



2009 Meeting At-A-Glance Day 2 Tuesday, April 21



10:15 AM - 11:30 AM

Panel Session 6

Imperial/Juilliard

6A: The New Face in Innovation in Big Pharma

Presented by: Alexandria Real Estate Equities, Inc.

Given current economic conditions, and dwindling pipelines, big pharma is investing in biotech companies to acquire promising drug candidates through M&A, licenses and collaborations. Following acquisitions, pharma is operating these entities as stand alone R&D divisions to retain their innovative and nimble cultures. In this panel you will learn first-hand (1) what pharmas are looking for, (2) how best to position your company to take advantage of these unique circumstances and (3) why access to great science, a strong talent pool, diverse sources of capital and a unique location will make your company a more attractive partner for big pharma.

Panel Chairman: Joel S. Marcus, CEO, Alexandria Real Estate Equities, Inc.

Panel Speakers: Dr. Jeremy Levin, Senior Vice President, Strategic Transactions, Bristol-Myers Squibb Company

Michelle Dipp, M.D., Ph.D., Vice President, Center of Excellence for External Drug Discovery, GSK

Ofra Weinberger, Director of Health Sciences, Columbia University

Carnegie/Lyceum

6B: Foreign Clinical Trials-Navigating the Quirks and Avoiding the Quagmires

Presented by: Chubb Group of Insurance Companies

An overview of the current environment with respects to regulation and insurance of clinical trials. Discussion will include the impact of ICH on the need for insurance, obstacles to expect and how to overcome them, and how to best protect your company's interests.

Panel Chairman: Juan Carlos Rehder, Life Science Specialist, Chubb Group of Insurance Companies

Panel Speakers: David Shuey, Executive Vice President, North American Life Science Practice Leader, Willis HRH

Deborah Turunjian, Clinical Operations Manager, OSI Pharmaceuticals, Inc.

Samir Shah, Vice President, Strategic Development, Research Pharmaceutical Services

Cesar Rios, Administration Officer, Chubb Group of Insurance Companies

Broadhurst

6C: Personalized Diagnostic tests for Cancer: What's Next?

Presented by: Easton Associates

Over the past five years, new diagnostic tests have become an essential part of cancer treatment and a key element in "personalized medicine". Our panel will discuss why these new tests now play such an important role in cancer diagnosis and treatment, and what will happen in the future, including:

1. What steps are pharma and biotech companies taking to include new diagnostic tests in their clinical trials?
2. How will medical oncologists and payers decide which tests are worth ordering (and paying for) and which not?
3. Genomic Health's OncoTypeDx obtained a reimbursement in excess of \$3,000 per test. Will tests that lead to better treatment choices and more survival, but not generate cost savings, get similar reimbursement?
4. At what stage in the "patient journey" will new tests will offer the greatest clinical value? See the most adoption?
5. What challenges do companies developing these new tests face?
6. Which types of laboratories will perform these tests?

Panel Chairman: Brian R. Buxton, MBA, Principal and Diagnostics Practice Leader, Easton Associates, LLC

Panel Speakers: Mara G Aspinall, M.B.A., President, Genzyme Genetics

Vijay Aggarwal, Ph.D, President & CEO, Aureon Laboratories

Walter P. Carney, Ph.D, President, Oncogene Science/Siemens Diagnostics

Aaron Bensimon, PhD, CEO, Genomic Vision



2009 Meeting At-A-Glance Day 2 Tuesday, April 21



10:15 AM - 11:30 AM

Alvin

Panel Session 6 (continued)

6D: Leveraging Generational and Cultural Diversity for Organizational Effectiveness

Presented by Opus Scientific LLC

Panelist will represent the training/development perspective, the legal issues and corporate management of a diverse workforce with respect to multi-generational and multi-cultural staff.

Panel Chairman: Linda Berke, President, Taylor Performance Solutions, Inc.

Panel Speakers: Diane Pfofenhauer, President, Employment Practices Advisors, Inc.

Casey DeBruyn, MSM Training Supervisor, Invitrogen Corporation

Shirley I. Kendall, Manager, Diversity Officer, Brookhaven National Lab

Belasco

6E: The Confluence of Legal Regulatory Issues Around Cleantech in Respect to Biofuel Technologies

Presented by: Sonnenschein Venture Technology Group

Panel discussing the issues facing start up companies in the biofuels area, including issues relating to governmental regulations, environmental, climate and infrastructure, carbon emissions, technology development, government grants and funding, IP and operational and how these issues interact and affect one another.

Panel Chairman: Joel N. Bock, Partner, Sonnenschein, Nath & Rosenthal

Panel Speakers: Kef Kasdin, General Partner, Battelle Ventures LP

Jeffrey C. Fort, Partner, Sonnenschein, Nath & Rosenthal

11:35 AM - 12:55 PM

Imperial/Juilliard

Panel Session 7

7A: Decreasing Bottom Line Costs in a Tight Economy

Presented by: New York Biotechnology Association

In tough economic times, companies need to take advantage of every opportunity to trim down their expenses.

In this panel you will get practical, concrete tips and strategies that can help you reduce the costs of doing business, from purchasing laboratory and office supplies to insurance and news distribution

Panel Chairman: Nathan Tinker, Executive Director, New York Biotechnology Association

Panel Speakers: Charles McWilliams, Director, Biotechnology Market Segment, VWR International

Tamy Dalal, Manager, Business Development/Strategic Alliances, Biotechnology Industry Organization

Neal Kwait, Purchasing, OSI Pharmaceuticals, Inc.

Carnegie/Lyceum

7B: The Future of BioSimilar, BioGenerics, Follow-on Biologics - A Rose by Any Other Name?

Presented by: The Weinberg Group

Both 2006 and 2007 witnessed hectic generic industry efforts to secure a legal abbreviated pathway for approval of lower-cost versions of sole source biologic and biotech products ("BioSimilar"). Progress stalled in the 2008 Election Year, with the brand and generic industries split widely, particularly on the length of non-patent data exclusivity that would protect new innovative biologics from lower cost competition under an abbreviated pathway. With the Obama Administration's budget proposing \$9.2 Billion in health care savings over 10 years via implementing a legal route for BioSimilar, will Congress make 2009 the year it finally enacts BioSimilar legislation? Legal, regulatory and scientific experts will offer both brand and generic perspectives on evolving views on the regulatory pathway likely to emerge for BioSimilar, highlighting both the opportunities and challenges for such products.

Panel Chairman: Michael Swit, Vice President, The Weinberg Group Inc.

Panel Speakers: Daniel Kracov, Esq., Partner, Chair of FDA & Healthcare Practice, Arnold & Porter LLP

Donna M. Praiss, Esq., Partner, Litigation & Intellectual Property Practice, Hunton & Williams LLP

Steven J. Lee, Esq., Partner, Chemical Life Sciences Practice Group, Kenyon & Kenyon LLP

David L. Rosen, B.S., Pharm., Esq., Partner, Co-chair, Life Sciences Industry Team, Foley & Lardner LLP



2009 Meeting At-A-Glance

Day 2 Tuesday, April 21



11:35 AM - 12:55 PM

Panel Session 7 (continued)

Broadhurst

7C: Are You At Risk-Legally? How to Protect the Company Without an In-House Legal Team and When and How to Build the In-House Legal

Presented by: Saul Ewing LLP

This panel will explore management's role and responsibility with respect to legal issues. We will provide information as to how management can spot issues that should be discussed with outside counsel when a company does not have an internal legal team. We will suggest methods for management to work with outside counsel efficiently and effectively. We will provide insight as to the appropriate time to hire in-house counsel (i.e. what to consider) and how to build the in-house legal team.

Panel Chairman: Robert L. Van Nostrand

Panel Speakers: Katayun I. Jaffari, Esq., Partner, Saul Ewing LLP

Barbara A. Wood, Esq., Senior Vice President General Counsel and Secretary, OSI Pharmaceuticals, Inc.

Tanya Berlage, Esq., Partner, Saul Ewing, LLP

Alvin

7D: Carrying the Weight of the World on Your Shoulders – Use Your Personal Style and Power to Lead Uncertain and Unpredictable Times

Presented by: Opus Scientific LLC

In this current challenging economic climate, much falls on the shoulders of the Human Resources Professional. How to use your personal style and power to lead your organization through an uncertain and unpredictable economic climate. You will learn day to day tools to be effective in your organization while maintaining work/life balance.

Panel Chairman: Gaylene Xanthopoulos, President, The Leadership Edge, Inc.

Panel Speakers: June Cohen, MA, Licensed Mental Health Counselor

Belasco

7E: Biotech Patent Pools

Presented by: Proskauer Rose LLP

Patent pools have been used for many years in other industries to create numerous efficiencies and overcome patent bottlenecks that impede the adoption of new technologies. While it is widely acknowledged that patent thickets in the biotech and pharmaceutical sectors may retard innovation, patent pools have not fully emerged as a solution to reduce licensing transaction costs, reduce risk, return a reasonable reward to IP owners, and increase the sharing of information and the adoption of technology. This panel will draw from the experience of highly successful patent pools in the consumer electronics sector managed by MPEG LA. Panelists will present observations and analysis from MPEG LA's unique experience and principles, as applied to current problems and concerns in the biotech and pharmaceutical industries. Where will biotech patent pools emerge and when? How might these pools be structured, given the issues which characterize this industry?

Panel Chairman: Kristin H. Neuman, Senior Counsel, Proskauer Rose LLP

Panel Speakers: Larry Horn, President & CEO, MPEG LA

Kenneth Rubenstein, Partner, Proskauer Rose LLP

Garrard R. Beeney, Sullivan & Cromwell LLP

1:00 PM - 2:30 PM

Westside Ballroom
North

Lunch and Plenary:

What is Big Pharma Looking for in Partnership Opportunities?

Moderated by: Sharon Mates, Chairman & CEO, Intra-Cellular Therapies, Inc.

Panelists: Dr. Reid Leonard, Executive Director of Worldwide Licensing and External Research, Merck

Robert Bagdorf, VP Worldwide Business Development, Pfizer, Inc.

Nick Manusos, Vice President for Licensing, Takeda Pharmaceuticals North America



Sharon Mates



Dr. Reid Leonard



Robert Bagdorf



Nick Manusos

2:30 PM

Conference Closes